Search results for "030203 arthritis & rheumatology"

showing 10 items of 355 documents

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren’s syndrome

2020

Abstract Objectives This phase 2 proof-of-concept study (NCT02610543) assessed efficacy, safety and effects on salivary gland inflammation of seletalisib, a potent and selective PI3Kδ inhibitor, in patients with moderate-to-severe primary Sjögren’s syndrome (PSS). Methods Adults with PSS were randomized 1:1 to seletalisib 45 mg/day or placebo, in addition to current PSS therapy. Primary end points were safety and tolerability and change from baseline in EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) score at week 12. Secondary end points included change from baseline at week 12 in EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI) score and histological features in salivary …

Male0301 basic medicineSalivamedicine.medical_specialtyPyridinesprimary Sjögren’s syndromeAdministration Oralprimary Sjogren's syndromePlaceboProof of Concept StudyGastroenterologySalivary Glandshistologyseletalisib03 medical and health sciences0302 clinical medicineDouble-Blind MethodRheumatologyInternal medicineproof-of-conceptmedicineHumansPharmacology (medical)Adverse effect030203 arthritis & rheumatologySalivary glandbiologySurrogate endpointbusiness.industryMiddle Agedmedicine.diseaseSialadenitisphosphatidylinositol 3-kinase delta (PI3K delta)primary Sjögren's syndrome3. Good healthSjogren's Syndrome030104 developmental biologymedicine.anatomical_structureTolerabilityImmunoglobulin MAntirheumatic Agentsphosphatidylinositol 3-kinase delta (PI3Kδ)Quinolinesbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemalebusiness
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey

2016

Background The aim was to establish how patients experience the impact of spondyloarthritis (SpA) on work disability and working life. Methods The survey was performed in 17/20 regions in Italy (1 January to 31 March 2013). A multiple-choice questionnaire was published on the official website of the sponsor - the National Association of Rheumatic Patients (ANMAR) - and hard-copies were distributed at outpatient clinics for rheumatic patients. Results Respondents (n = 770) were of both sexes (56 % men), educated (62 % at high school or more), of working age (75 % aged ≤60 years), and affected by SpA. The most common types diagnosed were ankylosing spondylitis (AS) (39 %) and psoriatic arthri…

MaleAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Adult; Aged; Arthritis Psoriatic; Employment; Female; Humans; Italy; Male; Middle Aged; Self Report; Spondylitis Ankylosing; Surveys and Questionnaires; Absenteeism; Disability Evaluation; Quality of Life; Rheumatology; Immunology and Allergy; ImmunologySettore MED/16 - REUMATOLOGIAWPIAlternative medicinePsoriaticDisability Evaluation0302 clinical medicineSurveys and QuestionnairesAbsenteeismSurveys and QuestionnaireImmunology and Allergy030212 general & internal medicineSurveyAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPIWorking lifeWork disabilityMiddle AgedSpondyloarthritis Survey Absenteeism Presenteeism WPIItalyAbsenteeismFemaleResearch ArticleHumanAdultEmploymentAnkylosingmusculoskeletal diseasesmedicine.medical_specialtyImmunology03 medical and health sciencesQuality of life (healthcare)RheumatologySpondyloarthritismedicineHumansSpondylitis AnkylosingSelf reportAged030203 arthritis & rheumatologyAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Adult; Aged; Arthritis Psoriatic; Employment; Female; Humans; Italy; Male; Middle Aged; Self Report; Spondylitis Ankylosing; Surveys and Questionnaires; Absenteeism; Disability Evaluation; Quality of Life; Immunology and Allergy; Rheumatology; Immunologybusiness.industryArthritisArthritis PsoriaticPresenteeismAbsenteeism; Presenteeism; Spondyloarthritis; Survey; WPI; Rheumatology; Immunology; Immunology and AllergyFamily medicinePresenteeismQuality of LifeSelf ReportSpondyloarthritibusinessSpondylitisArthritis Research & Therapy
researchProduct

Knee osteoarthritis and risk of hypertension: A longitudinal cohort study

2018

Whilst previous research has indicated an association between osteoarthritis and cardiovascular disease, it remains unclear whether people with osteoarthritis are at greater risk of developing hypertension. The aim of this study was to answer this uncertainity. We used the data of the Osteoarhritis Iniative, an ongoing public and private longitudinal study including people at higher risk of osteoarthritis or having knee osteoarthritis. Knee osteoarthritis was defined through radiological and clinical assessment. Incident hypertension was defined as a systolic blood pressure >140 mmHg and/or a diastolic value >90 mmHg. Multivariate Cox’s regression analyses were constructed where the p…

MaleAgingLongitudinal studymedicine.medical_specialtySystoleDiastoleBlood PressureOsteoarthritisDisease03 medical and health sciences0302 clinical medicineDiastoleRisk FactorsInternal medicineEpidemiologyHumansMedicineLongitudinal Studies030212 general & internal medicineSystoleAged030203 arthritis & rheumatologybusiness.industryIncidence (epidemiology)Original ArticlesMiddle AgedOsteoarthritis Kneemedicine.diseaseBlood pressureHypertensionFemaleGeriatrics and Gerontologybusinessosteoarthritis hypertension cardiovascular disease epidemiologyFollow-Up Studies
researchProduct

Hyperuricemia, cardiovascular profile, and comorbidity in older men and women: The Pro.V.A. Study

2017

Hyperuricemia (HU) is growing worldwide and associates with several medical conditions in the elderly. However, data about older people and possible gender differences are sparse. The aim of this study was to compare HU prevalence rates and association with relevant medical disorders in elderly subjects of both sexes. Pro.V.A. is a survey of 3099 individuals aged 65+, focusing on chronic diseases and disability. Uric acid (UA) levels were dichotomized using 6.0 mg/dL (females) and 7.0 mg/dL (males), and multivariate logistic regression models were used to estimate odds ratios (ORs) between HU and single comorbidity. HU prevalence was 21.5% in females and 15.8% in males. HU was associated wi…

MaleAgingmedicine.medical_specialtyPrevalenceComorbidityHyperuricemia030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineEpidemiologymedicineOdds RatioPrevalenceHumansHyperuricemiaLife StyleAged030203 arthritis & rheumatologyAnthropometrybusiness.industryCase-control studyOdds ratioAnthropometrymedicine.diseaseComorbidityUric AcidLogistic ModelsItalyCardiovascular DiseasesCase-Control StudiesPhysical therapyFemalecardiovascular diseases comorbidity elderly gender hypertension hyperuricemiaGeriatrics and GerontologybusinessBody mass index
researchProduct

Association between lower limb osteoarthritis and incidence of depressive symptoms: data from the osteoarthritis initiative

2016

Background: osteoarthritis (OA) is associated with a number of medical morbidities. Although the prevalence of depression and depressive symptoms is presumed to be high in people with OA, no prospective comparative study has analyzed its incidence. Objective: to determine whether OA was associated with an increased odds of developing depressive symptoms. Design: longitudinal cohort study (follow-up: 4.2 years). Setting: data were gathered from the North American Osteoarthritis Initiative (OAI) dataset. Subjects: people at higher risk developing OA. Methods: OA diagnosis was defined as the presence of OA at hand, knee, hip, back/neck or other sites at baseline. Depressive symptoms were defin…

MaleAgingmedicine.medical_specialtyTime FactorsComorbidityOsteoarthritisLogistic regressionOsteoarthritis HipOdds03 medical and health sciences0302 clinical medicineRisk FactorsSurveys and QuestionnairesInternal medicineEpidemiologyOdds RatiomedicineHumansLongitudinal StudiesProspective Studies030212 general & internal medicineosteoarthritis depression depressive symptoms epidemiology older peopleDepression (differential diagnoses)Aged030203 arthritis & rheumatologyChi-Square DistributionDepressionbusiness.industryIncidenceIncidence (epidemiology)ConfoundingGeneral MedicineOdds ratioMiddle AgedOsteoarthritis Kneemedicine.diseaseUnited StatesLogistic ModelsMental HealthMultivariate AnalysisPhysical therapyFemaleGeriatrics and GerontologybusinessAge and Ageing
researchProduct

Absence of Anti-Glomerular Basement Membrane Antibodies in 200 Patients With Systemic Lupus Erythematosus With or Without Lupus Nephritis: Results of…

2020

IntroductionAnti-glomerular basement membrane (GBM) antibodies are pathogenic antibodies first detected in renal-limited anti-GBM disease and in Goodpasture disease, the latter characterized by rapidly progressive crescentic glomerulonephritis combined with intra-alveolar hemorrhage. Studies have suggested that anti-GBM antibody positivity may be of interest in lupus nephritis (LN). Moreover, severe anti-GBM vasculitis cases in patients with systemic lupus erythematosus (SLE) have been described in the literature, but few studies have assessed the incidence of anti-GBM antibodies in SLE patients.ObjectiveThe main study objective was to determine if positive anti-GBM antibodies were present …

MaleAnti-Glomerular Basement Membrane Disease[SDV]Life Sciences [q-bio]Lupus nephritisAucunurologic and male genital diseasesSeverity of Illness IndexGastroenterologyanti-glomerular basement membrane antibodies0302 clinical medicinesystemic lupus erythematosusLupus Erythematosus SystemicImmunology and Allergy030212 general & internal medicineOriginal Researchmedicine.diagnostic_testbiologyanti-GBM glomerulonephritisGlomerular basement membraneIIfMiddle Aged3. Good healthTitermedicine.anatomical_structure[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleAntibodyVasculitisAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialtyImmunology03 medical and health sciencesAntigenInternal medicineanti-GBM antibodiesmedicineHumansAutoantibodiesRetrospective Studies030203 arthritis & rheumatologylupus nephritisbusiness.industryGoodpasture diseasemedicine.diseaseCase-Control StudiesImmunoassaybiology.proteinbusinesslcsh:RC581-607BiomarkersFrontiers in Immunology
researchProduct

Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.

2018

International audience; Objective - To compare long-term efficacy of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. Methods - The 28-month Maintenance of Remission using Rituximab in Systemic ANCA-associated Vasculitis trial compared rituximab with azathioprine to maintain remission in patients with newly diagnosed or relapsing granulomatosis with polyangiitis, microscopic polyangiitis or renal-limited ANCA-associated vasculitis. Thereafter, prospective patient follow-up lasted until month 60. The primary endpoint was the major-relapse rate at month 60. Relapse and serious adverse event-free …

MaleAzathioprineKaplan-Meier Estimateurologic and male genital diseasesGastroenterologySeverity of Illness Index0302 clinical medicineimmune system diseasesRecurrenceRisk FactorsAzathioprineClinical endpointImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasestreatmentRemission InductionMiddle Aged3. Good healthTreatment OutcomeAntirheumatic AgentsRituximabFemalesystemic vasculitisGranulomatosis with polyangiitisMicroscopic polyangiitisVasculitisRituximabImmunosuppressive Agentsmedicine.drugSystemic vasculitisAdultmedicine.medical_specialtyImmunologyAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGeneral Biochemistry Genetics and Molecular BiologyDrug Administration ScheduleAntibodies Antineutrophil Cytoplasmic03 medical and health sciencesRheumatologyInternal medicinemedicineHumanscardiovascular diseasesLymphocyte CountGlucocorticoidsAnti-neutrophil cytoplasmic antibodyAged030203 arthritis & rheumatology[SDV.GEN]Life Sciences [q-bio]/Geneticsgranulomatosis with polyangiitisDose-Response Relationship Drugbusiness.industrymedicine.diseaserespiratory tract diseases[ SDV.GEN ] Life Sciences [q-bio]/GeneticsbusinessAnnals of the rheumatic diseases
researchProduct

Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept

2016

Background: Data from routine clinical practice are needed to further define the efficacy and safety of biologic medications in children with juvenile idiopathic arthritis (JIA). The aim of this analysis was to investigate the disease status, reasons for discontinuation and adverse events in Italian JIA patients treated with etanercept (ETN). Methods: In 2013, all centers of the Italian Pediatric Rheumatology Study Group were asked to make a census of patients given ETN after January 2000. Patients were classified in three groups: group 1 = patients still taking ETN; group 2 = patients discontinued from ETN for any reasons; group 3 = patients lost to follow-up while receiving ETN. All three…

MaleBiologic therapieBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Rheumatology; Immunology and AllergyArthritisJuvenilePediatricsInflammatory bowel diseaseEtanerceptEtanerceptTNF inhibitorsSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineQuality of lifeRetrospective StudieImmunology and AllergyPediatric rheumatology030212 general & internal medicineChildBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyDrug SubstitutionBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcome; Pediatrics Perinatology and Child Health; Immunology and Allergy; RheumatologyAntirheumatic AgentPerinatology and Child Health3. Good healthTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAChild PreschoolAntirheumatic AgentsFemaleResearch ArticleHumanmedicine.drugBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitors; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Child; Child Preschool; Cross-Sectional Studies; Drug Substitution; Etanercept; Female; Humans; Male; Methotrexate; Patient Outcome Assessment; Retrospective Studies; Treatment Outcomemedicine.medical_specialtyAdolescent03 medical and health sciencesJuvenile idiopathic arthritiRheumatologyInternal medicineBiologic therapies; Etanercept; Juvenile idiopathic arthritis; Pediatric rheumatology; TNF inhibitorsmedicineHumansPediatrics Perinatology and Child HealthAdverse effectPreschoolRetrospective StudiesCross-Sectional Studie030203 arthritis & rheumatologybusiness.industryArthritisRetrospective cohort studyJuvenile idiopathic arthritismedicine.diseaseArthritis JuvenileRheumatologyDiscontinuationPatient Outcome AssessmentBiologic therapiesCross-Sectional StudiesMethotrexatePediatrics Perinatology and Child HealthPhysical therapybusinessTNF inhibitor
researchProduct

Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis

2019

Abstract Objectives In patients with LN, clinical and histological responses to treatment have been shown to be discordant. We investigated whether per-protocol repeat kidney biopsies are predictive of LN relapses and long-term renal function impairment. Methods Forty-two patients with incident biopsy-proven active proliferative (class III/IV±V) LN from the database of the UCLouvain were included in this retrospective study. Per-protocol repeat biopsies were performed after a median [interquartile range (IQR)] time of 24.3 (21.3–26.2) months. The National Institutes of Health activity index (AI) and chronicity index (CI) scores were assessed in all biopsies. Results Despite a moderate corre…

MaleBiopsy030232 urology & nephrologyKidneyGastroenterologychemistry.chemical_compound0302 clinical medicinesystemic lupus erythematosusRecurrenceInterquartile rangePharmacology (medical)Proteinuriamedicine.diagnostic_testHazard ratioPrognosisLupus NephritisProteinuriaKidney TubulesCreatinineDisease ProgressionhistopathologyFemaleRenal biopsymedicine.symptomRituximabImmunosuppressive AgentsAdultlong-term outcomemedicine.medical_specialtyRenal functionMethylprednisoloneYoung Adult03 medical and health sciencesrenal biopsyRheumatologyInternal medicineBiopsymedicineHumansImmunologic FactorsCyclophosphamideGlucocorticoidsProportional Hazards ModelsRetrospective Studieslupus nephritisrepeat biopsy030203 arthritis & rheumatologyCreatininebusiness.industryrenal functionMycophenolic AcidchemistryPulse Therapy DrugHistopathologybusinessRheumatology
researchProduct